Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14120402 | 0.96 | ACHE (0.37) | ALDH1A1MAPTMAPK1LMNAMAOA | |
| SCHEMBL31385136 | 0.82 | ALDH1A1 (0.40) | ALDH1A1MAPTMAPK1LMNAMAOA | |
| SCHEMBL3205385 | 0.81 | MAOA (0.44) | ALDH1A1MAPTMAPK1LMNAMAOA | |
| SCHEMBL28937922 | 0.81 | ALDH1A1 (0.36) | ALDH1A1MAPTMAPK1LMNAMAOA | |
| SCHEMBL30748287 | 0.81 | SIRT2 (0.39) | ALDH1A1MAPTMAPK1LMNAMAOA | |
| SCHEMBL16397656 | 0.81 | SIRT2 (0.39) | ALDH1A1MAPTMAPK1LMNAMAOA | |
| SCHEMBL3218869 | 0.81 | MAOA (0.44) | ALDH1A1MAPTMAPK1LMNAMAOA | |
| SCHEMBL2818508 | 0.81 | ALDH1A1 (0.41) | ALDH1A1MAPTMAPK1LMNAMAOA | |
| SCHEMBL30917672 | 0.81 | MAOA (0.41) | ALDH1A1MAPTMAPK1LMNAMAOA | |
| SCHEMBL30083746 | 0.81 | ALDH1A1 (0.36) | ALDH1A1MAPTMAPK1LMNAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263656-B2 | Substituted aminotetralines | HOFFMANN-LA ROCHE INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263656-B2 | Substituted aminotetralines | HOFFMANN-LA ROCHE INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263656-B2 | Substituted aminotetralines | HOFFMANN-LA ROCHE INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | GALLEY GUIDO (DE) | 2012-03-22 | — | — | US | disclosed |
| WO-2010018109-A2 | SUBSTITUTED AMINOTETRALINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041713-A1 | SUBSTITUTED AMINOTETRALINES | FIROOZNIA FARIBORZ | 2010-02-18 | — | — | US | disclosed |
| US-20100041713-A1 | SUBSTITUTED AMINOTETRALINES | FIROOZNIA FARIBORZ | 2010-02-18 | — | — | US | disclosed |
| US-20100041713-A1 | SUBSTITUTED AMINOTETRALINES | FIROOZNIA FARIBORZ | 2010-02-18 | — | — | US | disclosed |
| EP-1981499-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007085558-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| US-5753655-A | PROGESTINS OR ANTIPROGESTINS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | CRY1, PER2, GPR119 | ALDH1A1 1716/4885MAPT 31/4885MAPK1 3205/4885 |
| US-20100041713-A1 | SUBSTITUTED AMINOTETRALINES | HRH4, HRH1, HRH2 | ALDH1A1 1500/4885MAPT 3548/4885MAPK1 3971/4885 |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | CRY1, PER2, GPR119 | ALDH1A1 1541/4885MAPT 33/4885MAPK1 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.